Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Immune Checkpoint Inhibitors – Special Topics – Special Topics: Trends and Market Dynamics
Immune checkpoint inhibitors have transformed many oncology settings since their entry into the marketplace just over a decade ago. They are continuing to advance into earlier lines of therapy,…
Antibody-Drug Conjugates – Special Topics – Special Topics: Trends and Market Dynamics
Antibody-drug conjugates have solidified their position as valuable tools against cancer. The agents combine the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. The…
Alzheimer’s Disease – Special Topics – Special Topics: Caregiver Perspectives on Diagnostics and Leqembi in the Treatment of Alzheimer’s Disease (US)
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…
Dry and Wet Age-Related Macular Degeneration – Special Topics – Special Topics: Gene Therapies in Ophthalmology (US)
The wet age-related macular degeneration (AMD) market in the United States is replete with intravitreal (IVT) therapies—including Regeneron’s Eylea, Roche / Genentech’s Lucentis and Vabysmo,…
Alzheimer’s Disease – Special Topics – Special Topics: Physician Awareness, Perceptions, and Use of Leqembi (US)
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…
Immune Checkpoint Inhibitors | Special Topics | Trends and Market Dynamics – Multi Indication | G7 | 2023
Immune checkpoint inhibitors have had a transformative impact in many oncology settings since their entry into the marketplace a little over a decade ago. Their use continues to advance into…
Antibody-Drug Conjugates | Special Topics | Trends and Market Dynamics – Multi-indication | G7 | 2023
Antibody-drug conjugates have proven to be a versatile and effective tool in treating a wide range of tumor types, establishing the drug class as a valuable weapon against cancer. The approval of…
Antibody-Drug Conjugates | Special Topics | Trends and Market Dynamics – Multi-indication | G7 | 2022
Antibody-drug conjugates have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of…
Coronavirus COVID-19 – Special Topics – Special Topics: COVID-19 Treatment and Management (G7 )
The treatment landscape for coronavirus disease 2019 (COVID-19) continues to evolve rapidly. Despite the availability of vaccines in the markets under study, research is ongoing to lower viral…
Major Depressive Disorder (DSM-V) – Special Topics – Special Topics: Novel Drugs in Psychiatry (US)
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
